Merit Medical Systems Inc

The recent capitulation flush bar marks a potential end to forced selling, but price remains in a Stage 4 decline. Medium-term bias is bearish against falling EMAs and no stabilization bounce. Short-term price is extended and at extreme oversold, offering no clear timing edge. Execution calls for deferred selling, trimming into any rally near resistance.

• ↑Q1 revenue $381.9M up 7% YoY; net income $56.7M, EPS $0.94.
• ↑Free cash flow reached $25M, up 26% YoY, boosting financial flexibility.
• ↓Q1 OEM revenue down 14% YoY, pressuring overall profitability.